Video

Dr. Sauter on Key Considerations for Posttransplant Pembrolizumab in T-cell NHL

Craig Sauter, MD, discusses important considerations regarding the use of pembrolizumab after autologous stem cell transplant in T-cell non-Hodgkin lymphoma.

Craig Sauter, MD, director, Blood and Marrow Transplant Program, Hematology and Medical Oncology, Cleveland Clinic, discusses important considerations regarding the use of pembrolizumab (Keytruda) after autologous stem cell transplant in T-cell non-Hodgkin lymphoma (NHL).

Despite a phase 2 trial (NCT02362997) meeting its primary end point of improved progression-free survival at 18 months, it was conducted in a limited and specific cohort of 21 subjects, Sauter explains. Based on the limited patient population, this could lower the level of statistical confidence, and caution should accordingly be exercised when extrapolating results.

Additionally, the incidence of immune-related adverse effects (AEs) was aligned with expectations based on previous safety data, Sauter continues. High-dose chemotherapies are associated with transient toxicity periods and can often result in immune-related AEs, such as myeloid neoplasia after treatment desists, Sauter says.

Further investigation of a larger multicenter cohort trial is required to confirm the benefit of posttransplant consolidation therapy in this patient subset, he concludes. 

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center